MMMonica Mbabazi

Monica Mbabazi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Monica Mbabazi has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pulmonary Tuberculosis Is Associated with Body Site-Specific Alterations in the Respiratory and Gut Microbiome in Uganda

    by Monica Mbabazi, Joanitah Nabwire, Naome Mutesi, Edgar Kigozi, Sharon Namiiro, Adrian Muwonge, David Patrick Kateete

    Background: Tuberculosis is a major infectious disease whose effects may extend beyond the lungs to influence microbial communities at other body sites. Although studies have reported alterations in the respiratory and gut microbiomes of people with TB, evidence from sub-Saharan Africa remains limited, and the extent to which these alterations differ between body sites is not fully understood. This study characterized sputum and stool microbiomes among Ugandan adults with pulmonary TB and those without TB. Methods: We conducted a cross-sectional study involving 200 participants, comprising 150 adults with pulmonary TB and 50 contacts, at Mulago National Referral Hospital in Kampala, Uganda. Sputum and stool samples were profiled using 16S rRNA gene sequencing. Following quality control and contaminant removal, within-sample diversity was assessed using multiple alpha diversity indices. Beta diversity was evaluated using distance-based methods, with group differences assessed by permutational multivariate analysis of variance (PERMANOVA) and homogeneity of dispersion tests. Differentially abundant taxa were identified using ANCOM-BC2. Results: After quality control, 135 sputum and 151 stool samples were retained for downstream analysis. In sputum, microbial richness estimators Chao1 and ACE were lower among TB cases than controls, whereas differences in overall community composition were not statistically significant after correction for multiple testing. In stool, several richness and diversity measures differed between groups, and beta-diversity analyses detected differences in community composition. However, TB cases exhibited greater within-group dispersion, and the sequencing platform contributed substantially to variation in stool microbial profiles. In multivariable analyses, the sequencing platform was the only factor independently associated with stool community composition after correction for multiple testing. Differential-abundance analyses identified body site-specific taxonomic associations with TB, including differences involving Streptococcus , Parvimonas , and Actinobacillus in sputum, and Dorea , Lachnoclostridium , and Turicibacter in stool. Conclusion: Pulmonary TB was associated with differences in microbial richness and the abundance of specific taxa in both sputum and stool, but evidence for overall community composition differences varied by body site and was influenced by dispersion and sequencing platform. These findings highlight the importance of examining both respiratory and gut microbial communities in TB research. Longitudinal studies using standardized sequencing methods are needed to clarify how these patterns change during treatment and whether they have diagnostic or clinical relevance.

  • Open Access

    Whole-genome characterization of Plasmodium falciparum population structure and drug resistance across Uganda and neighboring countries

    by Shahiid Kiyaga, Monica Mbabazi, Thomas Katairo, Victor Asua, Francis D. Semakuba, Bienvenu Nsengimaana, Stephen Tukwasibwe, Innocent Wiringilimaana, Jackie Nakasaanya, Jerry Mulondo, et al.

    Uganda has one of the world’s highest malaria burdens, but parasite population structure and connectivity have not been characterized nationally with whole-genome data. We analyzed 249 monoclonal Plasmodium falciparum genomes from 26 sentinel sites across Uganda in 2023 and compared them with publicly available genomes from five neighboring countries. Genetic diversity was high and differentiation low in Uganda, but identity-by-descent detected limited structure. This was most pronounced in the low-transmission southwest, where parasites shared ancestry and recent relatedness with isolates from western Tanzania. Selection scans identified signals at loci associated with resistance to artemisinins and their partner drugs, and to chloroquine and antifolates. The strongest signal was at PfPX1 where the PIN haplotype (L1222P, M1701I, D1705N) reached 70% prevalence nationwide, but selection was carried by PIN haplotypes that had additionally acquired D384A, largely confined to northern and eastern Uganda. A second substitution at the same codon, D384Y, formed a haplotype shared across the Tanzanian border. PfKelch13 variants were partitioned across multiple backgrounds, consistent with repeated independent emergence, and C469Y was enriched on the PfPX1 D384A-PIN background. These genomes provide a 2023 baseline for tracking potential mediators of drug resistance and support coordinated genomic surveillance across Uganda and its neighbors.


  • Open Access

    PfPHAST: Plasmodium falciparum Public Health Amplicon Sequencing Tool, a Streamlined Panel for Malaria Genomic Surveillance

    by Francis D. Semakuba, Bienvenu Nsengimaana, Monica Mbabazi, Thomas Katairo, Kathryn Murie, Nicholas Hathaway, Innocent Wiringilimaana, John Vester Muwanika, Kore Lum, Milya Davlieva, et al.

    Genomic tools can support malaria control policy through surveillance of Plasmodium falciparum populations, tracking antimalarial drug resistance, pfhrp2/3 deletions that compromise rapid diagnostic tests, and selection at the circumsporozoite protein (PfCSP) vaccine target, as well as through molecular correction of therapeutic efficacy studies (TES). Multiplex Amplicons for Drug, Diagnostic, Diversity, and Differentiation Haplotypes using Targeted Resequencing (MAD 4 HatTeR), a comprehensive amplicon sequencing panel covering up to 276 targets, supports these applications but is tailored to research rather than routine programmatic use. We developed P. falciparum Public Health Amplicon Sequencing Tool (PfPHAST), a 56-target derivative of MAD 4 HatTeR spanning drug resistance loci, pfhrp2 / 3 deletion, PfCSP genotyping, non-falciparum species identification, and 20 high-heterozygosity microhaplotype loci for TES classification. We compared PfPHAST and MAD 4 HatTeR using laboratory strain controls, including two-strain dilution series and a five-strain mixture, across parasite densities of 100 to 10,000 parasites/µL. At matched per-target depth, PfPHAST achieved a higher quality-control pass rate than MAD4HatTeR (94.4% versus 90.0%) and distributed reads more evenly across targets. The panels showed comparable recall and precision for drug resistance codons and microhaplotypes, reaching near-complete recall above 40% within-sample allele frequency (WSAF) at all densities, with reduced sensitivity for minor alleles below 10% WSAF at low parasite density in both panels. Observed and expected WSAF correlated strongly for both panels, and both resolved a five-strain polyclonal mixture, including a 5% minor strain. By concentrating sequencing capacity on targets of greatest programmatic relevance, PfPHAST offers a scalable, lower-cost alternative to comprehensive research panels without sacrificing performance on shared targets, complementing MAD 4 HatTeR for routine molecular malaria surveillance.

  • Open Access

    Imported malaria predominates in near-elimination settings in Southwestern Uganda

    by Monica Mbabazi, Shahiid Kiyaga, Thomas Katairo, Kisakye D. Kabbale, Victor Asua, Brian A. Kagurusi, Innocent Wiringilimaana, Bienvenu Nsengimaana, Francis D. Semakuba, Jackie Nakasaanya, et al.

    Malaria transmission in southwestern Uganda is low, but persists despite control efforts. Identifying whether infections are locally sustained or imported by travelers is critical for guiding interventions. We integrated epidemiologic surveillance with parasite genomics to characterize imported malaria episodes at three health facilities in southwestern Uganda. Between January 2023 and June 2024, we enrolled microscopy-confirmed malaria cases at three health facilities, Maziba and Muko (very low transmission) and Kamwezi (low-to-moderate transmission), administered travel history questionnaires, and collected dried blood spots for genotyping. 348 Plasmodium falciparum infections were genotyped using MAD 4 HatTeR, a multiplex amplicon sequencing panel targeting 165 diversity markers and 38 drug resistance loci. Complexity of infection and pairwise relatedness were estimated using MOIRE and Dcifer, respectively. Plasmotrack, a transmission network framework, was used to infer transmission networks and importation rates. Amongst malaria cases, travel was common in Maziba (87%) and Muko (96%) but infrequent in Kamwezi (12%). Most travel in Maziba and Muko was from high-transmission regions in northern and eastern Uganda. Parasites in Maziba and Muko exhibited higher within-host diversity and lower within-site relatedness compared to those in Kamwezi, with the proportion of significant related infection pairs substantially lower in Maziba (0.59%) and Muko (0.17%) than in Kamwezi (6.36%). Transmission network inference identified most infections in Maziba and Muko as imported, with the majority of inferred secondary transmission linked to recent travelers. In contrast, Kamwezi showed multiple highly related clusters, indicating sustained local transmission. Validated markers of artemisinin resistance (K13 P441L and R561H) were more prevalent in Kamwezi. Malaria in Maziba and Muko was driven largely by importation from other parts of Uganda, while local transmission predominated in Kamwezi. Tailored interventions addressing travel-associated risks and local transmission, supported by travel histories and genetic data will be valuable to advance malaria elimination in this region.


  • Open Access

    Sustained high prevalence of multiple antimalarial drug resistance markers in Uganda in 2023–2024

    by Thomas Katairo, Victor Asua, Francis D. Semakuba, Bienvenu Nsengimaana, Shahiid Kiyaga, Nicholas Hathaway, Kathryn Murie, Stephen Tukwasibwe, Innocent Wiringilimaana, Jackie Nakasaanyaa, et al.

    The emergence and spread of drug resistance threaten malaria control in Uganda. This study reports new data on key polymorphisms associated with antimalarial drug sensitivity at 32 malaria reference centers in Uganda in 2023 and 2024. Ten thousand thirty samples were collected from patients aged >6 months presenting with uncomplicated falciparum malaria and sequenced using the MAD 4 HatTeR panel and Illumina platforms; of these, 8,518 passed quality control and were analyzed. Multiple validated or candidate K13 mutations associated with artemisinin partial resistance were detected at ≥20% prevalence at one or more sites across multiple timepoints. The K13 mutations A675V and C469Y predominated in northern Uganda, P441L was most common in western Uganda, and R561H and C469F were confined to southwestern Uganda. After rapid increases in earlier years, prevalences of K13 mutations plateaued at most sites, with A675V, C469Y, and P441L reaching maximum site prevalences of 40%, 58%, and 46%, respectively. Prevalence of the chloroquine resistance marker CRT K76T was generally low but increased substantially at three sites in northwestern Uganda, rising to 38% at the last timepoint, with CRT H97L, newly reported in Africa, following a similar trend. The antifolate resistance quintuple mutant haplotype remained highly prevalent nationwide. In addition, DHPS A581G and DHFR I164L, markers of higher-level antifolate resistance, were most common in southwestern Uganda with prevalences up to 64% and 76%, respectively; DHFR I164L also expanded into central and eastern regions. These results highlight continued geographic heterogeneity and underscore the need for continued, nationwide molecular surveillance to guide treatment and chemoprevention policies.


  • Open Access

    Microbiota-Based Machine Learning Approaches for TB Diagnostics

    by Monica Mbabazi, Agasi Herbert, Nilay Peker, David Patrick Kateete, Adrian Muwonge

    Background: Machine learning (ML) applied to lung and gut microbiota offers substantial yet underexplored potential for improving tuberculosis (TB) diagnosis and prognosis. Progress has been limited by insufficiently large and standardised datasets. Here, we applied ML models to globally curated microbiota datasets to classify TB cases and healthy controls.Methods: Datasets are from our recently published systematic review of 42 studies (2010–2024) reporting microbiota changes associated with TB. The harmonised lung and gut datasets include n=1,617 participants. Six ML model types were optimised across 36 parameters for diagnostic (TB status) and prognostic (treatment status) classification. Models were trained, cross-validated, and independently validated using 70%, 20%, and 10% of each dataset, respectively.Findings: The dataset included 1,181 lung and 550 gut microbiota samples, of which 1,264 (73%) were microbiologically confirmed TB cases; 89% of samples originated from Africa and Asia. In the global lung dataset, Lasso II and Ridge II models achieved an area under the receiver operating characteristic curve (AUROC) of 0.93 and 0.92 during cross-validation and correctly classified 64 of 75 TB cases. External independent validation (n=94) showed comparable performance, correctly classifying 63 of 75 cases. Although Africa- and Asia-specific models performed similarly to global models during cross-validation, their performance did not generalise to external validation. Random Forest models performed best on treatment-phase lung samples and on gut microbiota datasets, achieving cross-validation metrics comparable to those from the lung analyses. Genera such as Rothia, Gemella, Prevotella, and Streptococcus consistently ranked among the strongest predictors of pulmonary TB, suggesting potential biomarker value.Interpretation: ML models leveraging lung and gut microbiota show promise as complementary tools for TB diagnosis, particularly for extrapulmonary or hard-to-diagnose cases. This work provides a foundation for clinical metagenomics in TB diagnostics and prognostics. To support reproducibility and future innovation, we release MLTBdx, an open-source pipeline and dataset.

  • Top Cited Papers
    Open Access

    Sustained High Prevalence of Multiple Antimalarial Drug Resistance Markers in Uganda in 2023-24

    by Thomas Katairo, Victor Asua, Francis D. Semakuba, Bienvenu Nsengimaana, Shahiid Kiyaga, Nicholas Hathaway, Kathryn Murie, Stephen Tukwasibwe, Innocent Wiringilimaana, Jackie Nakasaanya, et al.

    The emergence and spread of drug resistance threatens malaria control in Uganda. This study reports new data on key polymorphisms associated with antimalarial drug sensitivity at 32 malaria reference centers in Uganda in 2023 and 2024. Samples were collected from patients aged >6 months presenting with uncomplicated falciparum malaria, sequenced using the MAD 4 HatTeR panel and Illumina platforms. Multiple validated or candidate K13 mutations associated with artemisinin partial resistance were detected at ≥20% prevalence at one or more sites across multiple timepoints. The K13 mutations A675V and C469Y predominated in northern Uganda, P441L was most common in western Uganda, and R561H and C469F were confined to southwestern Uganda. After rapid increases in earlier years, prevalences of K13 mutations plateaued at most sites, with A675V, C469Y and P441L reaching maximum site prevalences of 40%, 58%, and 46%, respectively. Prevalence of the chloroquine resistance marker CRT K76T was generally low but increased substantially at three sites in northwestern Uganda, rising to 38% at the last timepoint, with CRT H97L, newly reported in Africa, following a similar trend. The antifolate resistance quintuple mutant haplotype remained highly prevalent nationwide. In addition, DHPS A581G and DHFR I164L, markers of higher-level antifolate resistance, were most common in southwestern Uganda with prevalences up to 64% and 76%, respectively; DHFR I164L also expanded into central and eastern regions. These results highlight continued geographic heterogeneity and underscore the need for continued, nationwide molecular surveillance to guide treatment and chemoprevention policies.


  • Open Access

    Imported malaria predominates in near-elimination settings in Southwestern Uganda

    by Monica Mbabazi, Shahiid Kiyaga, Thomas Katairo, Kisakye D. Kabbale, Victor Asua, Brian A. Kagurusi, Innocent Wiringilimaana, Bienvenu Nsengimaana, Francis D. Semakuba, Jackie Nakasaanya, et al.

    Background: Malaria transmission in southwestern Uganda is low, but persists despite ongoing control efforts. Identifying whether infections are locally sustained or imported by travelers is critical for guiding interventions. We integrated epidemiologic surveillance with parasite genomics to characterize imported malaria episodes at three health facilities in southwestern Uganda. Methods: Between January 2023 and June 2024, we enrolled microscopy-confirmed malaria cases at three health facilities, Maziba and Muko (very low transmission) and Kamwezi (low-to-moderate transmission), administered travel history questionnaires, and collected dried blood spots for genotyping. Plasmodium falciparum infections were genotyped using MAD 4 HatTeR, a highly sensitive multiplex amplicon sequencing panel targeting 165 diversity markers and 38 drug resistance loci. Complexity of infection and pairwise relatedness were estimated using MOIRE and Dcifer, respectively. Plasmotrack, a Bayesian transmission network framework, was used to infer network structure, transmission directionality, reproduction numbers, and importation rates. Results: Amongst malaria cases, recent overnight travel was common in Maziba (87%) and Muko (96%) but infrequent in Kamwezi (12%). Most travel in cases from Maziba and Muko was from high-transmission regions in northern and eastern Uganda. Parasites in Maziba and Muko cases exhibited higher within-host diversity and lower within-site relatedness compared to those in Kamwezi cases. Transmission network inference identified most infections in Maziba and Muko as imported, with the majority of inferred secondary transmission linked to recent travelers. In contrast, Kamwezi showed multiple highly related clusters, indicating sustained local transmission. Validated and candidate markers of artemisinin partial resistance (K13 P441L and R561H) were more prevalent in Kamwezi. Conclusion: Malaria in Maziba and Muko was driven largely by importation from other parts of Uganda, while local transmission played a larger role in Kamwezi . Tailored interventions addressing travel-associated risks and local transmission, supported by travel histories and parasite genetic data will be valuable to advance malaria elimination in this region.

  • Open Access

    The impact of tuberculosis and its treatment on the lung and gut microbiota: a global systematic review, meta-analysis, and amplicon-based metagenomic meta-analysis

    by Monica Mbabazi, David Patrick Kateete, Faith Nakazzi, Joanitah Nabwire Wandera, Naume Mutesi, Moses Ocan, Irene Andia Biraro, Andrew Abaasa, William Evan Johnson, Bryan Wee, et al.

    Tuberculosis (TB) remains the leading cause of bacterial disease-related mortality worldwide. While Koch’s single-agent model has long guided TB diag


  • Open Access

    The impact of tuberculosis and its treatment on the lung and gut microbiota: A global systematic review, meta-analysis, and amplicon-based metagenomic meta-analysis

    by Monica Mbabazi, David Patrick Kateete, Faith Nakazzi, Joanitah Nabwire Wandera, Naume Mutesi, Moses Ocan, Irene Andia Biraro, Andrew Abaasa, William Evan Johnson, Bryan Wee, et al.

    Background: Tuberculosis (TB) remains the leading cause of bacterial disease-related deaths worldwide. Historically, the Koch’s single-causative-agent model has shaped diagnostics, treatment, and prevention. However, metagenomic studies have unveiled the presence of a lung microbiome, which is disrupted by TB and its orally administered treatment, with downstream effects on the gut microbiome. These changes may hold diagnostic, prognostic, and control potential once better understood. Here, we systematically analyze 38 studies with 3,394 individuals with TB and health controls to assess global insights on the impact of TB and its treatment on lung and gut microbiome diversity, structure, and composition. A meta-analysis with 24 studies estimates this effect size, while a patient-level amplicon metagenomic meta-analysis with 1617 individuals with 1.3 billion reads validates these associations. This study followed PRISMA guidelines and a pre-registered PROSPERO protocol (CRD42022329763). Results: The systematic review reveals no global consensus on TB’s impact on the lung microbial diversity, though most studies report reduced diversity. However, we estimate a 0.14–0.41 overall reduction in lung and gut diversity. Patient-level lung diversity analysis showed no significant differences overall (Shannon index), though TB was associated with reduced diversity in China, but not in South Africa. In contrast, in the gut TB was associated with higher diversity in most countries. The TB diagnostic value of the microbiome remains uncertain, as disease status accounts for only 0.8–9% of lung and 1.8–9% of gut microbiota variation. However, lung depletion of Prevotella, Neisseria, Veillonella, Haemophilus, Fusobacterium, Pseudomonas, Streptococcus, Porphyromonas , and Treponema , along with gut depletion of Prevotella, Ruminococcus, Faecalibacterium, Clostridium, Roseburia, Rothia, Eubacterium, and Escherichia . TB treatment is associated with a reduction in diversity of both lung and gut. Conclusion: TB is generally linked to reduced microbial diversity in the lung, but not gut. In contrast, treatment consistently reduces diversity in both, depleting key core genera. These findings underscore the exploitable potential of the gut–lung axis to improve TB diagnostics and prognosis.